JNJ 87890387
Alternative Names: JNJ-0387; JNJ-87890387Latest Information Update: 20 Jun 2024
At a glance
- Originator Janssen Research & Development
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 08 Apr 2024 Pharmacodynamics data from a preclinical study in Solid tumors presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 12 Dec 2023 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Inoperable/Unresectable) in USA (Parenteral) (NCT06178614)